Back to search results

The NOMAD Study: Blood and Urine Screening for Cancer

This study, called The NOMAD Study, is looking for 10,000 healthy volunteers to help establish "normal" levels for new blood and urine tests designed to screen for cancer. You can join if you are 18 or older and do not have a known internal cancer or a history of one. Researchers will collect blood and urine samples from you and review your medical records. The main goal is to see how well these new tests work in people without cancer, which will help improve future cancer screening methods. This is an observational study, meaning you won't receive any specific treatment.

Study design
This is an observational study planning to enroll 10,000 participants. It is not specified if it is randomized or blinded.
What's involved
You would provide blood and urine samples, and your medical records would be reviewed. The duration of your participation is not specified.
Compensation
Not stated in the trial record.
Follow-up
Biospecimen archiving is planned for up to 20 years, but direct participant follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06192875

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~10,000 participants
Updated 2026-09-14 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Blood level distributions of methylated DNA tumor markers
Measured over Baseline
+2 more outcomes measured

Conditions

Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Healthy Volunteers

NCT06192875

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John B. Kisiel, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Ellie Omerdic
[email protected]
507-266-1874
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

10,000 patients without a known internal (non-cutaneous) cancer or a history of an internal cancer
To balance age, rough recruitment goals will be set for the following subsets: 18-39 years, 40-49 years , 50-59 years , 60-69 years , 70-79 years , and \>= 80 years
To balance sex, roughly half of the participants recruited within each age subset will be women
Roughly half of all participants will have had a colonoscopy or colon x-ray within the past 5 years, or Cologuard® test in the last 3 years which were negative for cancer and precancerous lesions
Roughly half of all participants will have had a chest x-ray within the past 5 years which was negative for cancer
Roughly half of women participants will have had a mammography in the past 5 years which was negative for cancer
An attempt will be made to recruit minimums (parentheses) of the following subsets: men with normal Prostate-specific antigen (PSA) level (200); diabetes mellitus (200); connective tissue diseases like rheumatoid arthritis, systemic lupus erythematosus, and scleroderma (100); chronic obstructive lung disease (100); inflammatory bowel disease or cirrhosis (100), and pancreatitis (100)
To assess the effects of other common covariates, specific recruitment targets will not be set. Rather, data obtained on all participants will include BMI, smoking (past/present), alcohol consumption, pregnant status (women), and selected medications (steroidal and non-steroidal anti-inflammatory drugs, statins, anti-hypertensives, and anti-depressants)

Exclusion

Patients has a past or current diagnosis of invasive cancer (this does not include basal cell or squamous cell skin cancers)
Patient has had a solid organ transplant
Inability to give informed consent
Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection
Patient has chronic indwelling urinary catheter
Patient has had a urinary tract infection within the 14 days prior to sample collection
Patient has known clinically significant xerostomia
Patient has known recent (within 30 days prior to collection) active upper respiratory tract infection or anogenital infection

What this trial measures

  • Blood level distributions of methylated DNA tumor markersBaseline

    Assessed through assays performed on blood plasma across a cohort of patients without known cancer or precancer to estimate specificity cutoff ranges.

  • Biospecimen archiveUp to study completion (estimate 20 years)

    Assessed by total number of blood samples collected. Collected blood samples will be used to facilitate assessment of clinical specificity in future molecular blood test studies or appraisal of test refinements.

  • Detection of cancer using urine samplesBaseline

    Assessed by number of urine samples used to assay methylated DNA markers (MDMs), RNA, or protein in cell free or extracellular vesicles.